J Curtis Nickel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4725064/publications.pdf

Version: 2024-02-01

246 papers 13,377 citations

62 h-index ²⁹³³³
108
g-index

251 all docs

251 docs citations

251 times ranked

5941 citing authors

#	Article	IF	CITATIONS
1	The bacterial microbiota of Hunner lesion interstitial cystitis/bladder pain syndrome. BJU International, 2022, 129, 104-112.	1.3	6
2	Chronic prostatitis/chronic pelvic pain syndrome-related pain symptoms and their impact on sexual functioning. Canadian Urological Association Journal, 2022, 16 , .	0.3	5
3	Rethinking the Role of Saw Palmetto Extract for Men with Lower Urinary Tract Symptoms in North America. Uro, 2022, 2, 137-150.	0.3	7
4	An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions. World Journal of Urology, 2021, 39, 2065-2071.	1.2	10
5	EDITORIAL COMMENTARY. Urology, 2021, 147, 117-118.	0.5	O
6	Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPPâ€I Research Network Study. Neurourology and Urodynamics, 2021, 40, 810-818.	0.8	7
7	The chicken or the egg: Longitudinal changes in pain and catastrophizing in women with interstitial cystitis/bladder pain syndrome. Canadian Urological Association Journal, 2021, 15, 326-331.	0.3	3
8	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Journal of Urology, 2021, 205, 755-760.	0.2	2
9	Psychological Assessment of a Female Patient with Chronic Pelvic Pain., 2021,, 23-32.		O
10	Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study. Journal of Urology, 2021, 205, 1430-1437.	0.2	22
11	Reply by Authors. Journal of Urology, 2021, 205, 1437-1437.	0.2	O
12	Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review. JMIR Research Protocols, 2021, 10, e21909.	0.5	O
13	Biopsychosocial predictors of suicide risk in patients with interstitial cystitis/bladder pain syndrome. Canadian Urological Association Journal, 2021, 15, E630-E636.	0.3	1
14	The Urinary Microbiome in Interstitial Cystitis/Bladder Pain Syndrome? A Critical Look at the Evidence. Journal of Urology, 2021, 206, 1087-1090.	0.2	1
15	Editorial Comment. Journal of Urology, 2021, 206, 1220.	0.2	O
16	Overview of seminal fluid biomarkers for the evaluation of chronic prostatitis: a scoping review. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	2
17	Urinary fungi associated with urinary symptom severity among women with interstitial cystitis/bladder pain syndrome (IC/BPS). World Journal of Urology, 2020, 38, 433-446.	1.2	14
18	Role of urinary cations in the etiology of interstitial cystitis: A multisite study. International Journal of Urology, 2020, 27, 731-735.	0.5	3

#	Article	IF	CITATIONS
19	Surgical therapy for benign prostatic hyperplasia: Almost three decades of change. Canadian Urological Association Journal, 2020, 14, 258.	0.3	0
20	It is premature to categorize Hunner Lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology, 2020, 54, 99-100.	0.6	3
21	Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99–100. Scandinavian Journal of Urology, 2020, 54, 357-357.	0.6	1
22	Hunner Lesion Interstitial Cystitis: The Bad, The Good, and The Unknown. European Urology, 2020, 78, e122-e124.	0.9	8
23	Analgesic prescribing habits and patterns of Canadian chief urology residents: A national survey. Canadian Urological Association Journal, 2020, 14, 199-203.	0.3	1
24	Chronic prostatitis/chronic pelvic pain syndrome: it is time to change our management and research strategy. BJU International, 2020, 125, 479-480.	1.3	13
25	Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future. Canadian Urological Association Journal, 2020, 14, 281-287.	0.3	22
26	Chronic Prostatitis/Chronic Pelvic Pain Syndrome. , 2020, , 287-302.		0
27	Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy. BJU International, 2019, 123, 91-97.	1.3	11
28	Depression and helplessness impact interstitial cystitis/bladder pain syndrome pain over time. Canadian Urological Association Journal, 2019, 13, 328-33.	0.3	11
29	Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. European Urology Focus, 2019, 5, 2-4.	1.6	16
30	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European Journal of Cancer, 2019, 112, 118-126.	1.3	36
31	Male CP/CPPS: where do we stand?. World Journal of Urology, 2019, 37, 1015-1022.	1.2	33
32	A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. Journal of Clinical Medicine, 2019, 8, 415.	1.0	37
33	Dangerous fluoroquinolones: The urologist's dilemma. Canadian Urological Association Journal, 2019, 14, 85-86.	0.3	5
34	Impact of 5αâ€reductase inhibitor and αâ€blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU International, 2019, 123, 511-518.	1,3	17
35	Possible drug-induced, vision-threatening maculopathy secondary to chronic pentosan polysulfate sodium (Elmiron®) exposure. Canadian Urological Association Journal, 2019, 14, 10-11.	0.3	9
36	Editorial Comment. Journal of Urology, 2019, 201, 555-555.	0.2	0

#	Article	IF	Citations
37	Post-Void Dribblingâ€"Is it Time to Take Another Look at a Common Urology Problem?. Journal of Urology, 2019, 201, 1064-1066.	0.2	3
38	Depression and CopingÂBehaviors Are Key Factors in Understanding Pain in Interstitial Cystitis/Bladder Pain Syndrome. Pain Management Nursing, 2018, 19, 497-505.	0.4	13
39	FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research. Journal of Urology, 2018, 200, 39-42.	0.2	26
40	The Interstitial Cystitis/Bladder Pain Syndrome Clinical Picture: A Perspective from Patient Life Experience. Urology Practice, 2018, 5, 286-292.	0.2	6
41	Management of chronic urologic pain: When the traditional model fails, ask your friends for help. Canadian Urological Association Journal, 2018, 12, S145.	0.3	1
42	Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Canadian Urological Association Journal, 2018, 12, 303-312.	0.3	74
43	Evaluation of the male with chronic prostatitis/chronic pelvic pain syndrome. Canadian Urological Association Journal, 2018, 12, S152-4.	0.3	2
44	Management of chronic prostatitis/chronic pelvic pain syndrome. Canadian Urological Association Journal, 2018, 12, S161-3.	0.3	19
45	Injection therapy for urologic chronic pelvic pain: Lessons learned. Canadian Urological Association Journal, 2018, 12, S186-8.	0.3	2
46	The X-Y factor: Females and males with urologic chronic pelvic pain syndrome present distinct clinical phenotypes. Canadian Urological Association Journal, 2018, 12, E270-5.	0.3	4
47	The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A look at 1310 patients over 16 years. Canadian Urological Association Journal, 2018, 12, 196-202.	0.3	19
48	Publish and/or perish: A urological perspective on predatory publications. Canadian Urological Association Journal, 2018, 12, 239-242.	0.3	5
49	Early experience with topical meloxicam and lidocaine combination for the treatment of vulvodynia. Canadian Urological Association Journal, 2018, 12, 252-255.	0.3	6
50	Canadian Urological Association best practice report on chronic scrotal pain. Canadian Urological Association Journal, 2018, 12, 161-72.	0.3	12
51	Medical marijuana for urologic chronic pelvic pain. Canadian Urological Association Journal, 2018, 12, S181-3.	0.3	6
52	Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain. Journal of Urology, 2017, 198, 122-128.	0.2	43
53	Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Urology, 2017, 103, 191-197.	0.5	43
54	Risk of Incident Antidepressantâ€Treated Depression Associated with Use of 5αâ€Reductase Inhibitors Compared with Use of αâ€Blockers in Men with Benign Prostatic Hyperplasia: A Populationâ€Based Study Using the Clinical Practice Research Datalink. Pharmacotherapy, 2017, 37, 517-527.	1.2	10

#	Article	IF	CITATIONS
55	Understanding pain and coping in women with interstitial cystitis/bladder pain syndrome. BJU International, 2017, 120, 286-292.	1.3	12
56	Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. World Journal of Urology, 2017, 35, 1525-1530.	1.2	1
57	Childhood bladder and bowel dysfunction predicts irritable bowel syndrome phenotype in adult interstitial cystitis/bladder pain syndrome patients. Canadian Urological Association Journal, 2017, 11, 255-9.	0.3	9
58	Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome. Canadian Urological Association Journal, 2017, 12, E100-4.	0.3	6
59	Treatment effectiveness in interstitial cystitis/bladder pain syndrome: Do patient perceptions align with efficacy-based guidelines?. Canadian Urological Association Journal, 2017, 12, E1-5.	0.3	22
60	Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia. Canadian Urological Association Journal, 2017, 11, 194.	0.3	5
61	Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clinical Epidemiology, 2017, Volume 9, 83-91.	1.5	19
62	Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate?. Investigative and Clinical Urology, 2017, 58, 149.	1.0	10
63	Racial differences in prostate inflammation: results from the REDUCE study. Oncotarget, 2017, 8, 71393-71399.	0.8	10
64	Practical Psychosocial Management of Urologic Chronic Pelvic Pain Syndromes., 2017,, 25-42.		1
65	When you meet your urologist: An open letter to our patients. Canadian Urological Association Journal, 2016, 10, 359.	0.3	0
66	CUA guideline: Diagnosis and treatment of interstitial cystitis/ bladder pain syndrome. Canadian Urological Association Journal, 2016, 10, 136.	0.3	104
67	Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. Journal of Urology, 2016, 196, 1493-1498.	0.2	59
68	Clinical Phenotyping Does Not Differentiate Hunner Lesion Subtype of Interstitial Cystitis/Bladder Pain Syndrome: AÂRelook at the Role of Cystoscopy. Journal of Urology, 2016, 196, 1136-1140.	0.2	53
69	Reply to Dino PapeÅj, Ana JeronÄjć's Letter to the Editor re: Giuseppe Magistro, Florian M.E. Wagenlehner, Magnus Grabe, Wolfgang Weidner, Christian G. Stief, J. Curtis Nickel. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 2016;69:286–97. European Urology, 2016, 70. e166-e167.	0.9	2
70	Editorial Comment. Journal of Urology, 2016, 196, 1348-1349.	0.2	0
71	Risk of erectile dysfunction associated with use of $5 \cdot \hat{l} \pm reductase$ inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ, The, 2016, 354, i4823.	3.0	29
72	Editorial Comment. Journal of Urology, 2016, 196, 440-441.	0.2	0

#	Article	IF	Citations
73	Assessment of the Lower Urinary Tract Microbiota during Symptom Flare in Women with Urologic Chronic Pelvic Pain Syndrome: A MAPP Network Study. Journal of Urology, 2016, 195, 356-362.	0.2	92
74	A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome. Journal of Urology, 2016, 196, 747-754.	0.2	38
75	Tanezumab Reduces Pain in Women with Interstitial Cystitis/Bladder Pain Syndrome and Patients with Nonurological Associated Somatic Syndromes. Journal of Urology, 2016, 195, 942-948.	0.2	37
76	Mechanisms of Quality of Life and Social Support in Inflammatory Bowel Disease. Journal of Clinical Psychology in Medical Settings, 2016, 23, 88-98.	0.8	27
77	Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. European Urology, 2016, 69, 286-297.	0.9	195
78	Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. Prostate, 2015, 75, 1492-1498.	1.2	20
79	Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis. PLoS ONE, 2015, 10, e0135484.	1.1	6
80	Role of Prostatic Inflammation in the Clinical Presentation of Benign Prostatic Hyperplasia. European Urology Supplements, 2015, 14, e1459-e1463.	0.1	8
81	Search for Microorganisms in Men with Urologic Chronic Pelvic Pain Syndrome: A Culture-Independent Analysis in the MAPP Research Network. Journal of Urology, 2015, 194, 127-135.	0.2	75
82	Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. Cancer Prevention Research, 2015, 8, 312-317.	0.7	27
83	The importance of antibiotic stewardship. Canadian Urological Association Journal, 2015, 9, 8.	0.3	0
84	Clinical and Psychological Parameters Associated with Pain Pattern Phenotypes in Women with Interstitial Cystitis/Bladder Pain Syndrome. Journal of Urology, 2015, 193, 138-144.	0.2	58
85	Pentosan Polysulfate Sodium for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: Insights from a Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2015, 193, 857-862.	0.2	95
86	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. Reviews in Urology, 2015, 17, 179-89.	0.9	0
87	Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada. Canadian Urological Association Journal, 2014, 8, 1.	0.3	2
88	A survey of cannabis (marijuana) use and self-reported benefit in men with chronic prostatitis/chronic pelvic pain syndrome. Canadian Urological Association Journal, 2014, 8, 901.	0.3	19
89	Building a foundation of honesty, integrity and transparency. Canadian Urological Association Journal, 2014, 8, 17.	0.3	0
90	Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Canadian Urological Association Journal, 2014, 8, 403.	0.3	59

#	Article	IF	Citations
91	Testosterone Supplementation in Hypogonadal Men on 5â€ARI Therapy. Sexual Medicine Reviews, 2014, 2, 75-78.	1.5	2
92	Multiple sensitivity phenotype in interstitial cystitis/bladder pain syndrome. Canadian Urological Association Journal, 2014, 8, 758.	0.3	18
93	Phenotype-directed Management of Interstitial Cystitis/Bladder Pain Syndrome. Urology, 2014, 84, 175-179.	0.5	49
94	Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer, 2014, 120, 190-196.	2.0	65
95	Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU International, 2013, 111, 114-121.	1.3	17
96	Understanding chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). World Journal of Urology, 2013, 31, 709-710.	1.2	19
97	National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. European Urology, 2013, 63, 953-959.	0.9	108
98	Editorial Comment. Urology, 2013, 82, 833.	0.5	1
99	A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis/chronic pelvic pain syndrome and their spouses. World Journal of Urology, 2013, 31, 733-739.	1.2	48
100	Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World Journal of Urology, 2013, 31, 747-753.	1.2	57
101	Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World Journal of Urology, 2013, 31, 755-760.	1.2	64
102	Pain management in urology training: A national survey of senior residents. Canadian Urological Association Journal, 2013, 7, 456.	0.3	6
103	Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) meta-analytical approach. Canadian Urological Association Journal, 2013, 7, 195.	0.3	16
104	Are we being seduced by a robot?. Canadian Urological Association Journal, 2013, 3, 359.	0.3	3
105	Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Canadian Urological Association Journal, 2013, 2, 16.	0.3	33
106	Do more BPH patients mean more urologists or just better management strategies?. Canadian Urological Association Journal, 2013, 4, 127.	0.3	0
107	Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. Canadian Urological Association Journal, 2013, 5, 410.	0.3	0
108	Psychosocial Risk Factors and Patient Outcomes for Bladder Pain Syndrome., 2013, , 141-162.		0

#	Article	IF	CITATIONS
109	Syndromes Associated with Bladder Pain Syndrome as Clues to its Pathogenesis. , 2013, , 103-115.		1
110	Continuous Intravesical Lidocaine Treatment for Interstitial Cystitis/Bladder Pain Syndrome: Safety and Efficacy of a New Drug Delivery Device. Science Translational Medicine, 2012, 4, 143ra100.	5.8	85
111	Mapping of Pain Phenotypes in Female Patients with Bladder Pain Syndrome/Interstitial Cystitis and Controls. European Urology, 2012, 62, 1188-1194.	0.9	71
112	Preliminary Assessment of Safety and Efficacy in Proof-of-Concept, Randomized Clinical Trial of Tanezumab for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urology, 2012, 80, 1105-1110.	0.5	44
113	Second Multicenter, Randomized, Double-blind, Parallel-group Evaluation of Effectiveness and Safety of Intravesical Sodium Chondroitin Sulfate Compared With Inactive Vehicle Control in Subjects With Interstitial Cystitis/Bladder Pain Syndrome. Urology, 2012, 79, 1220-1225.	0.5	58
114	Investigation of a Ca $\langle \sup \rangle 2 + \langle \sup \rangle$ Channel Î ± 2 δ Ligand for the Treatment of Interstitial Cystitis: Results of a Randomized, Double-Blind, Placebo Controlled Phase II Trial. Journal of Urology, 2012, 188, 817-823.	0.2	14
115	Contemporary Management of the Painful Bladder: A Systematic Review. European Urology, 2012, 61, 29-53.	0.9	104
116	SHOULD WE REALLY CONSIDER GLEASON 6 PROSTATE CANCER?. BJU International, 2012, 109, 645-646.	1.3	28
117	αâ€blockers, antibiotics and antiâ€inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU International, 2012, 110, 1014-1022.	1.3	79
118	Prostatitis and Related Conditions, Orchitis, and Epididymitis. , 2012, , 327-356.e12.		26
119	Lower urinary tract symptoms associated with prostatitis. Canadian Urological Association Journal, 2012, 6, S133-5.	0.3	2
120	α-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical Evidence. Reviews in Urology, 2012, 14, 56-64.	0.9	6
121	Spousal support decreases the negative impact of pain on mental quality of life in women with interstitial cystitis/painful bladder syndrome. BJU International, 2011, 108, 713-717.	1.3	25
122	Prostatitis and Chronic Pelvic Pain Syndrome in Men. Medical Clinics of North America, 2011, 95, 75-86.	1.1	8
123	Quercetin for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urologic Clinics of North America, 2011, 38, 279-284.	0.8	29
124	1432 TANEZUMAB THERAPY FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME (CP/CPPS): PRELIMINARY ASSESSMENT OF EFFICACY AND SAFETY IN A RANDOMIZED CONTROLLED TRIAL. Journal of Urology, $2011,185,.$	0.2	3
125	Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. Urology, 2011, 78, 641-646.	0.5	32
126	Self-reported Spousal Support Modifies the Negative Impact of Pain on Disability in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urology, 2011, 78, 1136-1141.	0.5	24

#	Article	IF	CITATIONS
127	Interstitial Cystitis/Bladder Pain Syndrome and Nonbladder Syndromes: Facts and Hypotheses. Urology, 2011, 78, 727-732.	0.5	51
128	Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled Study. Journal of Urology, 2011, 186, 125-131.	0.2	58
129	Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study. Journal of Urology, 2011, 186, 1313-1318.	0.2	30
130	Prostatitis. Canadian Urological Association Journal, 2011, 5, 306-315.	0.3	53
131	Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU International, 2011, 108, 388-394.	1.3	177
132	Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome; a case control study. Canadian Urological Association Journal, 2011, 5, 410-415.	0.3	34
133	Management of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome. JAMA - Journal of the American Medical Association, 2011, 305, 78.	3.8	224
134	A feasibility trial of a cognitive-behavioural symptom management program for chronic pelvic pain for men with refractory chronic prostatitis/chronic pelvic pain syndrome. Canadian Urological Association Journal, 2011, 5, 328-332.	0.3	32
135	Bloodletting and the management of localized prostate cancer. Canadian Urological Association Journal, 2011, 5, 159-160.	0.3	1
136	What is BPS and how should it be managed in real life clinical practice?. Canadian Urological Association Journal, 2011, 5, 119-119.	0.3	0
137	Prostatitis and Male Chronic Pelvic Pain Syndrome. , 2011, , 295-307.		0
138	Update on urologic pelvic pain syndromes: highlights from the 2010 international chronic pelvic pain symposium and workshop, august 29, 2010, kingston, ontario, Canada. Reviews in Urology, 2011, 13, 39-49.	0.9	10
139	SEDUCED BY A ROBOT. BJU International, 2010, 105, 581-582.	1.3	4
140	THE ROBOTIC REVOLUTION: THE SEDUCTION CONTINUES. BJU International, 2010, 105, 583-583.	1.3	3
141	Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU International, 2010, 106, 1252-1263.	1.3	52
142	Pregabalin for the Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized Controlled Trial. Archives of Internal Medicine, 2010, 170, 1586-1593.	4.3	82
143	Psychosocial Phenotyping in Women With Interstitial Cystitis/Painful Bladder Syndrome: A Case Control Study. Journal of Urology, 2010, 183, 167-172.	0.2	135
144	797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY. Journal of Urology, 2010, 183, .	0.2	1

#	Article	IF	Citations
145	Interstitial Cystitis/Painful Bladder Syndrome and Associated Medical Conditions With an Emphasis on Irritable Bowel Syndrome, Fibromyalgia and Chronic Fatigue Syndrome. Journal of Urology, 2010, 184, 1358-1363.	0.2	198
146	Phenotypically Directed Multimodal Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study Using UPOINT. Urology, 2010, 75, 1249-1253.	0.5	177
147	A Multicenter, Randomized, Double-blind, Parallel Group Pilot Evaluation of the Efficacy and Safety of Intravesical Sodium Chondroitin Sulfate Versus Vehicle Control in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Urology, 2010, 76, 804-809.	0.5	75
148	Prevalence and Impact of Bacteriuria and/or Urinary Tract Infection in Interstitial Cystitis/Painful Bladder Syndrome. Urology, 2010, 76, 799-803.	0.5	22
149	Effect of Amitriptyline on Symptoms in Treatment NaÃ-ve Patients With Interstitial Cystitis/Painful Bladder Syndrome. Journal of Urology, 2010, 183, 1853-1858.	0.2	174
150	Forensic dissection of a clinical trial: lessons learned in understanding and managing interstitial cystitis. Reviews in Urology, 2010, 12, e78-85.	0.9	0
151	Re: Clinical Phenotyping in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Interstitial Cystitis: A Management Strategy for Urologic Chronic Pelvic Pain Syndromes. European Urology, 2009, 56, 881.	0.9	11
152	Phenotypic approach to the management of chronic prostatitis/chronic pelvic pain syndrome. Current Prostate Reports, 2009, 7, 132-137.	0.1	0
153	Phenotypic approach to the Management of chronic prostatitis/chronic pelvic pain syndrome. Current Urology Reports, 2009, 10, 307-312.	1.0	28
154	A realâ€life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU International, 2009, 103, 56-60.	1.3	62
155	Prevalence, symptom impact and predictors of chronic prostatitisâ€like symptoms in Canadian males aged 16–19â€∫years. BJU International, 2009, 103, 1080-1084.	1.3	35
156	Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU International, 2009, 103, 910-918.	1.3	124
157	Clinical Phenotyping of Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Correlation With Symptom Severity. Urology, 2009, 73, 538-542.	0.5	167
158	Sexual Functioning, Catastrophizing, Depression, and Pain, as Predictors of Quality of Life in Women With Interstitial Cystitis/Painful Bladder Syndrome. Urology, 2009, 73, 987-992.	0.5	58
159	Clinical Phenotyping of Women With Interstitial Cystitis/Painful Bladder Syndrome: A Key to Classification and Potentially Improved Management. Journal of Urology, 2009, 182, 155-160.	0.2	182
160	Chronic Prostatitis/Chronic Pelvic Pain: The Syndrome. Journal of Urology, 2009, 182, 18-19.	0.2	88
161	The Relationship Among Symptoms, Sleep Disturbances and Quality of Life in Patients With Interstitial Cystitis. Journal of Urology, 2009, 181, 2555-2561.	0.2	22
162	A RANDOMIZED PLACEBO-CONTROLLED MULTICENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME. Journal of Urology, 2009, 181, 123-123.	0.2	8

#	Article	IF	Citations
163	Development of an evidence-based cognitive behavioral treatment program for men with chronic prostatitis/chronic pelvic pain syndrome. World Journal of Urology, 2008, 26, 167-172.	1.2	64
164	Category III chronic prostatitis/chronic pelvic pain syndrome: Insights from the national institutes of health chronic prostatitis collaborative research network studies. Current Urology Reports, 2008, 9, 320-327.	1.0	27
165	Alfuzosin and Symptoms of Chronic Prostatitis–Chronic Pelvic Pain Syndrome. New England Journal of Medicine, 2008, 359, 2663-2673.	13.9	164
166	Introduction. BJU International, 2008, 101, 1-1.	1.3	2
167	Role of α ₁ â€blockers in chronic prostatitis syndromes. BJU International, 2008, 101, 11-16.	1.3	120
168	The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial. European Urology, 2008, 54, 1379-1384.	0.9	358
169	Improvement in Sexual Functioning in Patients with Interstitial Cystitis/Painful Bladder Syndrome. Journal of Sexual Medicine, 2008, 5, 394-399.	0.3	33
170	Time to Initiation of Pentosan Polysulfate Sodium Treatment After Interstitial Cystitis Diagnosis: Effect on Symptom Improvement. Urology, 2008, 71, 57-61.	0.5	36
171	Treatment of chronic prostatitis/chronic pelvic pain syndrome. International Journal of Antimicrobial Agents, 2008, 31, 112-116.	1.1	40
172	Inflammation and Benign Prostatic Hyperplasia. Urologic Clinics of North America, 2008, 35, 109-115.	0.8	134
173	Clinical Significance of Nontraditional Bacterial Uropathogens in the Management of Chronic Prostatitis. Journal of Urology, 2008, 179, 1391-1395.	0.2	43
174	The multidisciplinary approach to defining the urologic chronic pelvic pain syndromes: report from a national institutes of health workshop, december 13-14, 2007, Baltimore, MD. Reviews in Urology, 2008, 10, 157-9.	0.9	3
175	Nutraceuticals in Prostate Disease: The Urologist's Role. Reviews in Urology, 2008, 10, 192-206.	0.9	74
176	Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Male Interstitial Cystitis: Enigmas and Opportunities. Urology, 2007, 69, S60-S63.	0.5	42
177	Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention Trial. Journal of Urology, 2007, 178, 896-901.	0.2	97
178	Sexual Function is a Determinant of Poor Quality of Life for Women With Treatment Refractory Interstitial Cystitis. Journal of Urology, 2007, 177, 1832-1836.	0.2	76
179	98: The Relationship Between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the Reduce Trial. Journal of Urology, 2007, 177, 34-35.	0.2	6
180	Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome. BJU International, 2007, 101, 071009190733001-???.	1.3	70

#	Article	IF	Citations
181	ORIGINAL RESEARCHâ€"COUPLES' SEXUAL DYSFUNCTION: Predictors of Sexual and Relationship Functioning in Couples with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Journal of Sexual Medicine, 2007, 4, 734-744.	0.3	31
182	Sexual and Relationship Functioning in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Their Partners. Archives of Sexual Behavior, 2007, 36, 301-311.	1.2	54
183	Category III chronic prostatitis/chronic pelvic pain syndrome: Insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Current Prostate Reports, 2007, 5, 141-148.	0.1	1
184	How Does the Pre-Massage and Post-Massage 2-Glass Test Compare to the Meares-Stamey 4-Glass Test in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome?. Journal of Urology, 2006, 176, 119-124.	0.2	160
185	Catastrophizing and Pain-Contingent Rest Predict Patient Adjustment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Journal of Pain, 2006, 7, 697-708.	0.7	120
186	Opioids for chronic prostatitis and interstitial cystitis: Lessons learned from the 11th World Congress on Pain. Urology, 2006, 68, 697-701.	0.5	34
187	The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Current Opinion in Urology, 2006, 16, 5-10.	0.9	51
188	The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU International, 2006, 97, 1242-1246.	1.3	55
189	The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Current Prostate Reports, 2006, 4, 132-137.	0.1	0
190	The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Current Urology Reports, 2006, 7, 282-287.	1.0	16
191	Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU International, 2005, 95, 571-574.	1.3	98
192	MANAGEMENT OF URINARY TRACT INFECTIONS: HISTORICAL PERSPECTIVE AND CURRENT STRATEGIES: PART 2— MODERN MANAGEMENT. Journal of Urology, 2005, 173, 27-32.	0.2	53
193	Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology, 2005, 65, 654-658.	0.5	170
194	Chronic bacterial prostatitis: An evolving clinical enigma. Urology, 2005, 66, 2-8.	0.5	55
195	Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: The Canadian PIE Study. Urology, 2005, 66, 935-940.	0.5	140
196	PENTOSAN POLYSULFATE SODIUM THERAPY FOR MEN WITH CHRONIC PELVIC PAIN SYNDROME: A MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED STUDY. Journal of Urology, 2005, 173, 1252-1255.	0.2	108
197	A RANDOMIZED CONTROLLED TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR TREATMENT REFRACTORY INTERSTITIAL CYSTITIS. Journal of Urology, 2005, 173, 1186-1191.	0.2	128
198	MANAGEMENT OF URINARY TRACT INFECTIONS: HISTORICAL PERSPECTIVE AND CURRENT STRATEGIES: PART 1—BEFORE ANTIBIOTICS. Journal of Urology, 2005, 173, 21-26.	0.2	51

#	Article	IF	Citations
199	Canadian guidelines for the management of benign prostatic hyperplasia. Canadian Journal of Urology, 2005, 12, 2677-83.	0.0	21
200	Natural history of urinary tract infection in a primary care environment in Canada. Canadian Journal of Urology, 2005, 12, 2728-37.	0.0	8
201	The three As of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inflammatories. What is the evidence? BJU International, 2004, 94, 1230-1233.	1.3	54
202	Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU International, 2004, 94, 1279-1282.	1.3	111
203	Dutasteride: profile report. Drugs and Therapy Perspectives, 2004, 20, 5-7.	0.3	0
204	FAILURE OF A MONOTHERAPY STRATEGY FOR DIFFICULT CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME. Journal of Urology, 2004, 172, 551-554.	0.2	101
205	Interstitial cystitis. Medical Clinics of North America, 2004, 88, 467-481.	1.1	73
206	TREATMENT OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME WITH TAMSULOSIN: A RANDOMIZED DOUBLE BLIND TRIAL. Journal of Urology, 2004, 171, 1594-1597.	0.2	167
207	IMPACT OF POST-EJACULATORY PAIN IN MEN WITH CATEGORY III CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME. Journal of Urology, 2004, 172, 542-547.	0.2	94
208	Ciprofloxacin or Tamsulosin in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Annals of Internal Medicine, 2004, 141, 581.	2.0	234
209	Interstitial cystitis: the paradigm shifts: international consultations on interstitial cystitis. Reviews in Urology, 2004, 6, 200-2.	0.9	21
210	The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion. Canadian Journal of Urology, 2004, 11, 2186-93.	0.0	14
211	Prostatitis: Diagnosis and classification. Current Prostate Reports, 2003, 1, 93-94.	0.1	0
212	Prostatitis: Diagnosis and classification. Current Urology Reports, 2003, 4, 259-260.	1.0	13
213	Recommendations for the evaluation of patients with prostatitis. World Journal of Urology, 2003, 21, 75-81.	1.2	47
214	A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis. Journal of Urology, 2003, 169, 1401-1405.	0.2	141
215	Leukocytes And Bacteria In Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Compared To Asymptomatic Controls. Journal of Urology, 2003, 170, 818-822.	0.2	189
216	Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology, 2003, 62, 425-429.	0.5	156

#	Article	IF	Citations
217	The use of $\hat{l}\pm 1$ -adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology, 2003, 62, 34-41.	0.5	34
218	Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology, 2003, 62, 614-617.	0.5	166
219	Dutasteride. Drugs and Aging, 2003, 20, 917-918.	1.3	1
220	The Patient With Chronic Epididymitis: Characterization Of An Enigmatic Syndrome. Journal of Urology, 2002, 167, 1701-1704.	0.2	60
221	Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology, 2002, 59, 870-876.	0.5	81
222	Cytologic evaluation of urine is important in evaluation of chronic prostatitis. Urology, 2002, 60, 225-227.	0.5	24
223	Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002, 60, 434-441.	0.5	660
224	Overview summary statement. Urology, 2002, 60, 1-4.	0.5	151
225	Clinical evaluation of the man with chronic prostatitis/chronic pelvic pain syndrome. Urology, 2002, 60, 20-22.	0.5	57
226	Leukocyte and Bacterial Counts Do Not Correlate With Severity of Symptoms in Men With Chronic Prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. Journal of Urology, 2002, 168, 1048-1053.	0.2	196
227	Demographic And Clinical Characteristics Of Men With Chronic Prostatitis: The National Institutes Of Health Chronic Prostatitis Cohort Study. Journal of Urology, 2002, 168, 593-598.	0.2	200
228	Demographic And Clinical Characteristics Of Men With Chronic Prostatitis:. Journal of Urology, 2002, , 593-598.	0.2	11
229	The patient with chronic epididymitis: characterization of an enigmatic syndrome. Journal of Urology, 2002, 167, 1701-4.	0.2	20
230	Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. Journal of Urology, 2002, 168, 593-8.	0.2	56
231	Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. Journal of Urology, 2002, 168, 1048-53.	0.2	57
232	PREDICTORS OF PATIENT RESPONSE TO ANTIBIOTIC THERAPY FOR THE CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. Journal of Urology, 2001, 165, 1539-1544.	0.2	131
233	PREVALENCE OF PROSTATITIS-LIKE SYMPTOMS IN A POPULATION BASED STUDY USING THE NATIONAL INSTITUTES OF HEALTH CHRONIC PROSTATITIS SYMPTOM INDEX. Journal of Urology, 2001, 165, 842-845.	0.2	403
234	Rat model of experimentally induced abacterial prostatitis. Prostate, 2000, 45, 201-206.	1.2	31

#	ARTICLE	lF	CITATIONS
235	Prostatitis: The Last Frontier. World Journal of Surgery, 2000, 24, 1197-1199.	0.8	5
236	THE NATIONAL INSTITUTES OF HEALTH CHRONIC PROSTATITIS SYMPTOM INDEX: DEVELOPMENT AND VALIDATION OF A NEW OUTCOME MEASURE. Journal of Urology, 1999, 162, 369-375.	0.2	853
237	THE NATIONAL INSTITUTES OF HEALTH CHRONIC PROSTATITIS SYMPTOM INDEX. Journal of Urology, 1999, , 369-375.	0.2	39
238	Reply to letter to the Editor. Canadian Journal of Urology, 1999, 6, 878.	0.0	1
239	RELATIVE EFFICACY OF VARIOUS EXOGENOUS GLYCOSAMINOGLYCANS IN PROVIDING A BLADDER SURFACE PERMEABILITY BARRIER. Journal of Urology, 1998, 160, 612-614.	0.2	42
240	Re: Ameliorative Effect of Allopurinol on Nonbacterial Prostatitis. Journal of Urology, 1997, 157, 628-628.	0.2	6
241	Transurethral Microwave Thermotherapy for Nonbacterial Prostatitis: A Randomized Double-Blind Sham Controlled Study Using New Prostatitis Specific Assessment Questionnaires. Journal of Urology, 1996, 155, 1950-1955.	0.2	139
242	Intravesical Hyaluronic Acid in the Treatment of Refractory Interstitial Cystitis. Journal of Urology, 1996, 156, 45-48.	0.2	135
243	Bacterial localization in antibiotic-refractory chronic bacterial prostatitis. Prostate, 1993, 23, 107-114.	1.2	101
244	Coagulase-Negative Staphylococcus in Chronic Prostatitis. Journal of Urology, 1992, 147, 398-400.	0.2	111
245	Amdinocillin Treatment of Catheter-Associated Bacteriuria in Rabbits. Journal of Infectious Diseases, 1989, 159, 1065-1072.	1.9	36
246	The Ecology and Pathogenicity of Urease-Producing Bacteria in the Urinary Tract. CRC Critical Reviews in Microbiology, 1988, 16, 37-79.	4.8	159